GREY:SBIYF - Post by User
Post by
Horn1369on Feb 17, 2012 12:28am
166 Views
Post# 19547672
Interesting read.
Interesting read.
"This is the first time one of our plant-derived recombinant proteins has been studied in humans and we were gratified to see that SBS-1000 performed in an equivalent manner to marketed recombinant human insulin with respect to pharmacologic activity and tolerability," said Dr. Maurice Moloney, Chief Scientific Officer and founder of SemBioSys. "We would anticipate that full results of this trial will be submitted to a future scientific conference once all data have been analyzed."
"These results represent a significant milestone for SemBioSys. We have now demonstrated that we can consistently obtain regulatory approval to grow our insulin safflower crops. We have shown that we can extract, purify and formulate insulin from plant seeds to USP and EP standards and finally, we have obtained regulatory approval in the US and Europe to administer SBS 1000 in a phase I/II clinical trial, where our insulin has been found to be biologically active without any unexpected adverse reactions," commented James Szarko, Chief Executive Officer at SemBioSys. "We are continuing optimization work targeted at streamlining the production process to further improve cost of goods."
https://www.drugs.com/clinical_trials/sembiosys-genetics-inc-announces-clinical-results-plant-produced-insulin-6888.html